Aptamers have gained a lot of momentum in the past decade. It is worth highlighting that in 2005, Macugen became the first and the only USFDA approved aptamer drug for treating age-related macular degeneration (AMD).    It has been reported that more than 15 million people in the US suffer from AMD alone with 200,000 cases annually across North America.  This indicates a high...